GeneDx Holdings (WGS) Cash from Financing Activities (2020 - 2026)

GeneDx Holdings has disclosed Cash from Financing Activities across 7 years of filings, most recently posting $38.6 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 181.31% year-over-year to $38.6 million; the TTM figure through Mar 2026 stood at $72.9 million (up 25.0% YoY), while the FY2025 annual figure was $48.0 million, up 8.75% from the prior year.
• Cash from Financing Activities improved to $38.6 million in Q1 2026, from $23.2 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for WGS reached as high as $198.1 million in Q2 2022 and fell as low as -$911000.0 in Q3 2023.
• The 5-year median for Cash from Financing Activities is $10.8 million (2025), against an average of $30.3 million.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 83011.25% — and 2024, when it slumped 105.29%.
• A 5-year view of Cash from Financing Activities shows it stood at $65000.0 in 2022, then surged by 72366.15% to $47.1 million in 2023, then plunged by 34.14% to $31.0 million in 2024, then declined by 25.24% to $23.2 million in 2025, then jumped by 66.39% to $38.6 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $38.6 million, $23.2 million, and $10.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.